Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced. Currently CEO of Roche Pharmaceuticals since ...

Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

Detailed price information for Applovin Corp Cl A (APP-Q) from The Globe and Mail including charting and trades.

Gilead Sciences (GILD ... anticipated impact of Medicare Part D reform on revenue growth,” said CEO Daniel O’Day. The so-called “Part D reform” refers to changes to Medicare Part ...

Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the rationale behind its decision. In an open letter, the company’s chief executive Daniel O’Day reveals ...

Pharmaceutical stock Gilead Sciences is the best performing ... for metastatic triple-negative breast cancer. CEO Daniel O'Day told analysts on the Q4 earnings call: As we shared at our HIV ...